Free Trial

Millennium Management LLC Has $13.56 Million Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Mineralys Therapeutics logo with Medical background

Millennium Management LLC increased its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 1,015.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,101,674 shares of the company's stock after buying an additional 1,002,941 shares during the period. Millennium Management LLC owned 2.21% of Mineralys Therapeutics worth $13,562,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC raised its position in shares of Mineralys Therapeutics by 55.4% in the fourth quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock valued at $13,319,000 after buying an additional 385,726 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Mineralys Therapeutics by 43.0% in the fourth quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock valued at $1,127,000 after buying an additional 27,531 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $202,000. Proficio Capital Partners LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $285,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Mineralys Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock valued at $2,645,000 after buying an additional 1,307 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MLYS has been the subject of several recent analyst reports. The Goldman Sachs Group cut their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. HC Wainwright restated a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday, May 13th. Guggenheim set a $48.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, Wall Street Zen upgraded Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

View Our Latest Report on Mineralys Therapeutics

Insider Transactions at Mineralys Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 1,296,296 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $13.50 per share, for a total transaction of $17,499,996.00. Following the completion of the acquisition, the director now owns 4,280,051 shares of the company's stock, valued at approximately $57,780,688.50. This represents a 43.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction on Friday, April 11th. The stock was sold at an average price of $12.06, for a total transaction of $129,729.42. Following the transaction, the chief financial officer now owns 215,340 shares of the company's stock, valued at $2,597,000.40. This trade represents a 4.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 104,579 shares of company stock worth $1,534,353. Corporate insiders own 25.56% of the company's stock.

Mineralys Therapeutics Trading Down 1.4%

NASDAQ MLYS traded down $0.23 on Tuesday, hitting $15.73. 946,814 shares of the company's stock were exchanged, compared to its average volume of 489,201. The stock has a 50-day moving average of $14.47 and a 200-day moving average of $12.55. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -4.32 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.23. As a group, analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Mineralys Therapeutics Company Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

See Also

Institutional Ownership by Quarter for Mineralys Therapeutics (NASDAQ:MLYS)

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines